MOLECULAR BASIS OF LATE INFANTILE NCL

婴儿晚期 NCL 的分子基础

• 批准号: 2852488
• 负责人: TERRY J LERNER
• 金额: $ 26.28万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-09-30 至 2002-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2852488
• 关键词: autosomal recessive trait; clinical research; disease /disorder classification; disease /disorder onset; family genetics; gene expression; gene mutation; genetic disorder diagnosis; genetic markers; genotype; human genetic material tag; human subject; infant human (0-1 year); laboratory mouse; linkage mapping; molecular cloning; molecular pathology; neurogenetics; neuronal ceroid lipofuscinosis

DESCRIPTION: (From Abstract) The long-term objective of this research is to understand the molecular basis of neuronal ceroid lipofuscinosis (NCL; Batten disease). NCL is the most common neurodegenerative disorder of childhood and is characterized by progressive mental deterioration, seizures, and vision loss. The hallmark of the disease is the accumulation of autofluorescent lipopigments in ultrastructural cytosomes in neurons and other cell types. Five major sub-types are now recognized on the basis of age-at-onset, clinical presentation, and ultrastructural morphology: infantile (INCL), found exclusively in the Finnish population; late infantile (LNCL); juvenile (JNCL); and adult (Kufs disease). With the possible exception of the adult form, inheritance is autosomal recessive. The incidence of NCL is estimated at 1-5/100,000. Despite intensive effort, the basic biochemical defect in NCL continues to elude researchers. There is no effective treatment for this fatal disease. The loci for the juvenile (CLN3), infantile (CLN1) types, and CLN5 have been mapped by genetic linkage analysis to chromosome 16p, 1p, and 13q respectively. The late infantile defect (CLN2) has not yet been mapped, although linkage analysis with tightly linked markers excludes it from the JNCL locus on chromosome 16 and the INCL locus on chromosome 1. The first goal of this current proposal is to use genetic linkage methods with highly polymorphic markers to localize and refine the map position of the CLN2. This information will be used to implement a positional cloning strategy for the isolation and subsequent characterization of the gene. Throughout this project period, candidate genes will be evaluated for their role in the pathogenesis of NCL by biochemical and histological studies and by our analysis of candidate JNCL genes. With the identification of closely-linked highly informative flanking markers, DNA-based pre-natal and pre-symptomatic diagnosis can be offered to at-risk families well before the actual cloning and characterization of the disease gene. The identification of mutations within the gene will allow carrier testing in selected populations. Knowledge of the molecular defect underlying LNCL will help elucidate the biochemical pathways involved in the pathogenesis of the disease, shed light on the possible cause of the other ceroid lipofuscinoses, and provide a starting point for the design of rational therapies.

描述：（从摘要）本研究的长期目标 是了解神经元蜡样质脂褐质沉积症的分子基础 (NCL; Batten病）。NCL是最常见的神经退行性疾病 儿童期疾病，其特征是进行性精神障碍， 恶化癫痫和视力丧失这种疾病的特征是 是超微结构中自发荧光脂色素的积累， 神经元和其他细胞类型中的细胞体。现在有五个主要的子类型 根据发病年龄、临床表现和 超微结构形态学：婴儿（INCL），仅见于 芬兰人群;晚期婴儿（LNCL）;青少年（JNCL）;和成人 (Kufs疾病）。可能除了成年人， 遗传是常染色体隐性遗传。NCL的发生率估计为 1-5/100,000.尽管做了大量的努力， NCL继续躲避研究人员。没有有效的治疗方法 这种致命的疾病。 幼年型（CLN 3）、婴儿型（CLN 1）和CLN 5的基因座具有 通过遗传连锁分析定位到染色体16 p、1 p和13 q 分别晚期婴儿缺陷（CLN 2）尚未被定位， 尽管紧密连锁标记的连锁分析将其排除在 染色体16上的JNCL基因座和染色体1上的INCL基因座。的 目前这项建议的第一个目标是使用遗传连锁方法 用高度多态性的标记定位和细化地图位置 关于CLN 2此信息将用于实现位置 用于分离和随后表征的克隆策略 基因在整个项目期间，候选基因将被 通过生物化学和免疫组织化学方法评价它们在NCL发病机制中的作用， 组织学研究和我们对候选JNCL基因的分析。 随着紧密连锁的高信息侧翼的鉴定 标记物、基于DNA的产前和症状前诊断可以 早在克隆之前就提供给有风险的家庭， 疾病基因的特征。突变的鉴定 将允许在选定的人群中进行携带者测试。 了解LNCL潜在的分子缺陷将有助于阐明 参与疾病发病机制的生化途径， 阐明其他蜡样脂褐质沉积症的可能原因， 为合理治疗的设计提供了一个起点。